Business Context and Reporting Period
This Form 8-K filing by IDEAYA Biosciences, Inc. (IDYA) reports a significant capital raising event. The report date is June 8, 2026, with the transaction closing on June 10, 2026. The company, incorporated in Delaware and headquartered in South San Francisco, California, executed an underwriting agreement to issue common stock and pre-funded warrants.
Key Financial Metrics
- Net Proceeds: Approximately $323.6 million received after deducting underwriting discounts, commissions, and estimated offering expenses.
- Shares Issued: 7,222,225 shares of Common Stock (including the full exercise of the underwriters' option).
- Pre-Funded Warrants: Warrants issued to purchase 5,555,576 shares of Common Stock.
- Public Offering Price: $27.00 per Share and $26.9999 per Pre-Funded Warrant.
- Underwriting Price: $25.38 per Share and $25.3799 per Pre-Funded Warrant.
- Underwriters: J.P. Morgan Securities LLC, Jefferies LLC, TD Securities (USA) LLC, UBS Securities LLC, and Cantor Fitzgerald & Co.
Material Changes
The primary material change is the substantial increase in liquidity through the completed public offering. The company successfully exercised the underwriters' option to purchase an additional 1,666,669 shares, increasing the total capital raised beyond the initial tranche. This filing does not provide comparative financial metrics (revenue, profit, or margins) as it is a current report focused on a specific transaction rather than a periodic financial statement.
Outlook, Risks, and Contingencies
- Lock-Up Agreement: The Company, its directors, and executive officers agreed not to sell or transfer any Common Stock for 60 days following the date of the Prospectus without written consent from the Representatives.
- Indemnification: The Company agreed to indemnify the Underwriters against certain liabilities under the Securities Act of 1933.
- Warrant Terms: Pre-Funded Warrants are exercisable from the date of issuance until fully exercised, subject to ownership limitations.
Investor Verification Checklist
- Verify the final net proceeds of $323.6 million against the company's cash balance in subsequent filings.
- Confirm the dilution impact of the 7,222,225 new shares and 5,555,576 warrant shares on existing shareholders.
- Monitor the 60-day lock-up expiration date for potential selling pressure from insiders.
- Review the use of proceeds disclosed in the related prospectus supplement (not included in this 8-K text) to understand strategic allocation.